Be Clinical Raises Seed Funding for Skincare Innovation

In a significant development for the Indian premium skincare market, Be Clinical has successfully closed a seed funding round, securing INR 21 Crore (approximately $2.5 million USD). The investment was spearheaded by Sauce, with crucial participation from V3 Ventures (an affiliate of Verlinvest SA) and a notable cohort of angel investors. This infusion of capital signals strong market confidence in Be Clinical's evidence-led approach to addressing age-related skin concerns.

Founded in May 2025 by Hemangi Dhir, Be Clinical distinguishes itself through a rigorous commitment to clinically validated formulations and dermatologically active ingredients. The brand's inception followed two years of dedicated research and development, focusing specifically on the unique challenges presented by Indian skin types and environmental factors. This meticulous process, including in-house manufacturing to ensure stringent quality control, underpins the brand's promise of efficacy and safety.

The recent funding will fuel Be Clinical's strategic expansion. Key areas of investment include bolstering research and development capabilities to drive product innovation and broaden the existing clinical skincare portfolio. The company also plans to scale its manufacturing operations to meet escalating consumer demand and explore new domestic and international market entry points. This strategic allocation of resources aims to solidify Be Clinical's position as a leader in science-backed skincare accessible to a wider Indian consumer base.

The Indian skincare market, valued at over $15 billion and projected for robust growth, is increasingly shifting towards products that offer demonstrable results and transparency. Be Clinical's focus on clinical validation and active ingredients aligns perfectly with this evolving consumer preference. The brand's early traction, evidenced by over 1.2 lakh orders and strong repeat purchase rates since its launch, underscores the market's appetite for scientifically grounded solutions.

Zoeb Ali Khan, Vice President at Sauce, highlighted the company's full-stack model, encompassing in-house R&D, manufacturing, and clinically tested formulations, as a key differentiator. He noted, "We see this evidence-led approach as a genuine differentiator in the category, and feel this market & demographic is untapped." Similarly, Arjun Vaidya, Co-founder and Managing Partner at V3 Ventures, expressed enthusiasm for doubling down on their investment, citing the business's 5x sales growth while maintaining profitability and the company's strong competitive moat derived from in-house manufacturing.

Founder Hemangi Dhir emphasized the significance of the investment as validation of the brand's mission. "This investment gives us the ability to invest deeper in R&D, strengthen our manufacturing and clinical capabilities, build a stronger team, and take Be Clinical to more consumers across India," she stated. The capital injection is expected to accelerate Be Clinical's journey in making advanced, science-backed skincare solutions more attainable for consumers seeking effective anti-aging treatments.